Bioavailability of subutaneous low-molecular-weight heparin to patients on vasopressors

Lancet

Volumn 359, Issue 9309, 2002, Pages 849-850

  Dörffler Melly, Janine ^a,b   De Jonge, Evert ^a   De Pont, Anne Cornelie ^a   Meijers, Joost ^a   Vroom, Margreet B ^a   Büller, Harry R ^a   Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DOPAMINE; HYPERTENSIVE FACTOR; LOW MOLECULAR WEIGHT HEPARIN; NORADRENALIN; PHENYLEPHRINE; ANTICOAGULANT AGENT; VASOCONSTRICTOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENERAL SURGERY; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; BIOAVAILABILITY; CLINICAL TRIAL; DRUG INTERACTION; LETTER; METABOLISM; MIDDLE AGED; POSTOPERATIVE PERIOD; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; VASOCONSTRICTOR AGENTS;

EID: 0037045781     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07920-5     Document Type: Article

References (4)

1. Deep vein thrombosis and its prevention in critically ill adults
2. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
3. Prevention of deep vein thrombosis after hip replacement: Randomised comparison between unfractionated heparin and low molecular weight heparin
4. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa-,anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery